Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 20/20 | 0.87 |
| ▸ | ADRB3 | P13945 | 20/20 | 0.87 |
| ▸ | ADRB1 | P08588 | 17/20 | 0.87 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4432394 | 0.93 | ADRB3 (1.00) | ADRB2ADRB3ADRB1 | |
| SCHEMBL4430206 | 0.92 | ADRB3 (1.00) | ADRB2ADRB3ADRB1 | |
| SCHEMBL6664332 | 0.92 | ADRB2 (1.00) | ADRB2ADRB3ADRB1 | |
| SCHEMBL4723441 | 0.91 | ADRB3 (0.87) | ADRB2ADRB3ADRB1 | |
| SCHEMBL6661190 | 0.90 | ADRB3 (0.83) | ADRB2ADRB3ADRB1 | |
| SCHEMBL6664389 | 0.86 | ADRB3 (1.00) | ADRB2ADRB3ADRB1 | |
| SCHEMBL6681778 | 0.85 | ADRB3 (0.88) | ADRB2ADRB3ADRB1 | |
| SCHEMBL4431300 | 0.85 | ADRB3 (1.00) | ADRB2ADRB3ADRB1 | |
| SCHEMBL4435801 | 0.85 | ADRB3 (1.00) | ADRB2ADRB3ADRB1 | |
| SCHEMBL4553648 | 0.85 | ADRB3 (1.00) | ADRB2ADRB3ADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8207174-B2 | Beta-3 adrenergic receptor agonists; urinary tract infections, incontinence, gastrointestinal disorders, dysmenorrhea, obesity; tocolytic, anxiolytic, antidiabetic agents; antidepressants; 4-(2-hydroxy-3-(1-(5-phenylthieno[2,3-d]pyrimidin-4-yl)piperidin-4-ylamino)propoxy)phenol | 4SC AG (DE) | 2012-06-26 | — | — | US | claimed |
| US-20080249114-A1 | ARYLOXYPROPANOLAMINES, METHODS OF PREPARATION THEROF AND USE OF ARYLOXYPROPANOLAMINES AS MEDICAMENTS | SCHWARZ PHARMA AG (DE) | 2008-10-09 | — | — | US | claimed |
| US-8207174-B2 | Beta-3 adrenergic receptor agonists; urinary tract infections, incontinence, gastrointestinal disorders, dysmenorrhea, obesity; tocolytic, anxiolytic, antidiabetic agents; antidepressants; 4-(2-hydroxy-3-(1-(5-phenylthieno[2,3-d]pyrimidin-4-yl)piperidin-4-ylamino)propoxy)phenol | 4SC AG (DE) | 2012-06-26 | — | — | US | disclosed |
| US-8207174-B2 | Beta-3 adrenergic receptor agonists; urinary tract infections, incontinence, gastrointestinal disorders, dysmenorrhea, obesity; tocolytic, anxiolytic, antidiabetic agents; antidepressants; 4-(2-hydroxy-3-(1-(5-phenylthieno[2,3-d]pyrimidin-4-yl)piperidin-4-ylamino)propoxy)phenol | 4SC AG (DE) | 2012-06-26 | — | — | US | disclosed |
| US-8207174-B2 | Beta-3 adrenergic receptor agonists; urinary tract infections, incontinence, gastrointestinal disorders, dysmenorrhea, obesity; tocolytic, anxiolytic, antidiabetic agents; antidepressants; 4-(2-hydroxy-3-(1-(5-phenylthieno[2,3-d]pyrimidin-4-yl)piperidin-4-ylamino)propoxy)phenol | 4SC AG (DE) | 2012-06-26 | — | — | US | disclosed |
| US-20080249114-A1 | ARYLOXYPROPANOLAMINES, METHODS OF PREPARATION THEROF AND USE OF ARYLOXYPROPANOLAMINES AS MEDICAMENTS | SCHWARZ PHARMA AG (DE) | 2008-10-09 | — | — | US | disclosed |
| US-20080249114-A1 | ARYLOXYPROPANOLAMINES, METHODS OF PREPARATION THEROF AND USE OF ARYLOXYPROPANOLAMINES AS MEDICAMENTS | SCHWARZ PHARMA AG (DE) | 2008-10-09 | — | — | US | disclosed |
| US-20080249114-A1 | ARYLOXYPROPANOLAMINES, METHODS OF PREPARATION THEROF AND USE OF ARYLOXYPROPANOLAMINES AS MEDICAMENTS | SCHWARZ PHARMA AG (DE) | 2008-10-09 | — | — | US | disclosed |
| EP-1947103-A1 | Aryloxypropanolamines, methods of preparation thereof and use of aryloxypropanolamines as medicaments | 4SC AG (DE) | 2008-07-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080249114-A1 | ARYLOXYPROPANOLAMINES, METHODS OF PREPARATION THEROF AND USE OF ARYLOXYPROPANOLAMINES AS MEDICAMENTS | ADRB3, ADRB1, ADRB2 | ADRB2 3/4885ADRB3 1/4885ADRB1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.